Luteinizing Hormone-Releasing Hormone (LH-RH)
Need Assistance?
  • US & Canada:
    +
  • UK: +

Luteinizing Hormone-Releasing Hormone (LH-RH)

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Luteinizing hormone releasing hormone (LH-RH) is a reproductive hormone.

Category
Others
Catalog number
BAT-010196
CAS number
86073-88-3
Molecular Formula
C60H73N15O13
Molecular Weight
1212.3
Luteinizing Hormone-Releasing Hormone (LH-RH)
IUPAC Name
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Synonyms
Salmon-gnrh; Gnrh, salmon-; Salmon-LHRH; LHRH (salmon)
Purity
≥95%
Sequence
XHWSYGWLPG
Storage
Store at -20°C
Solubility
Soluble in DMSO
InChI
InChI=1S/C60H73N15O13/c1-32(2)20-47(60(88)75-19-7-12-49(75)59(87)65-28-50(61)78)73-55(83)44(22-34-25-63-40-10-5-3-8-38(34)40)69-52(80)29-66-53(81)43(21-33-13-15-37(77)16-14-33)70-58(86)48(30-76)74-56(84)45(23-35-26-64-41-11-6-4-9-39(35)41)71-57(85)46(24-36-27-62-31-67-36)72-54(82)42-17-18-51(79)68-42/h3-6,8-11,13-16,25-27,31-32,42-49,63-64,76-77H,7,12,17-24,28-30H2,1-2H3,(H2,61,78)(H,62,67)(H,65,87)(H,66,81)(H,68,79)(H,69,80)(H,70,86)(H,71,85)(H,72,82)(H,73,83)(H,74,84)/t42-,43-,44-,45-,46-,47-,48-,49-/m0/s1
InChI Key
NMJREATYWWNIKX-XJIZABAQSA-N
Canonical SMILES
CC(C)CC(C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8
1. Luteinizing hormone-releasing hormone antagonists
Gábor Mezo, Marilena Manea Expert Opin Ther Pat. 2009 Dec;19(12):1771-85. doi: 10.1517/13543770903410237.
Background: Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity. Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications. Objective/method: Here we give an overview of the most relevant LH-RH antagonists and their therapeutic applications. Recently patented compounds as well as drug formulations and dosage are presented. Conclusion: LH-RH antagonists have found clinical applications in in vitro fertilization, benign prostatic hyperplasia, endometriosis and in the treatment of hormone-dependent tumors. Work in progress is focused on further development of both peptidic and orally active non-peptidic LH-RH antagonists.
3. [The radioimmunological assaying of the luteinizing hormone-releasing hormone (LH-RH) in human beings. A general review (author's transl)]
B Teuwissen, K Thomas J Gynecol Obstet Biol Reprod (Paris). 1981;10(4):315-33.
The authors attempted to work out a synthesis of the known factors about the specifications required for the levels of LH-RH and for finding this hormone in different human biological milieux. Searching for endogenous LH-RH in women, men and children has given very different results. The disparity between the levels that have been found, which are often at the very limits of detection by the methods used, can be explained by the type of specification of the level and by the effects of the biological milieu used and by the breakdown of endogenous LH-RH in the living organism. The conclusion is that the values that have been found up to now are not really reliable and of no great use in human clinical work.
Online Inquiry
Verification code
Inquiry Basket